Symbols / MBOT Stock $2.20 +0.92% Microbot Medical Inc.

Healthcare • Medical Instruments & Supplies • United States • NCM
MBOT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Instruments & Supplies
CEO Mr. Harel Gadot
Exch · Country NCM · United States
Market Cap 147.75M
Enterprise Value 68.68M
Income -13.14M
Sales —
FCF (ttm) -8.32M
Book/sh 1.16
Cash/sh 1.17
Employees 43
Insider 10d —
IPO Mar 25, 1992
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.67
PEG 0.70
P/S —
P/B 1.90
P/C —
EV/EBITDA -4.67
EV/Sales —
Quick Ratio 23.04
Current Ratio 23.33
Debt/Eq 1.11
LT Debt/Eq —
EPS (ttm) -0.29
EPS next Y -0.33
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-26
Earnings (prior) 2026-03-26
ROA -21.04%
ROE -32.42%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 67.16M
Shs Float 67.16M
Insider Own 0.00%
Instit Own 17.54%
Short Float 12.02%
Short Ratio 4.83
Short Interest 8.06M
52W High 4.67
vs 52W High -52.89%
52W Low 1.60
vs 52W Low 37.50%
Beta 1.19
Impl. Vol. 1.22%
Rel Volume 0.48
Avg Volume 2.13M
Volume 1.03M
Target (mean) $7.50
Tgt Median $5.50
Tgt Low $5.00
Tgt High $12.00
# Analysts 3
Recom Strong_buy
Prev Close $2.18
Price $2.20
Change 0.92%
About

Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.50
Mean price target
2. Current target
$2.20
Latest analyst target
3. DCF / Fair value
$-2.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.20
Low
$5.00
High
$12.00
Mean
$7.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-14 reit HC Wainwright & Co. Buy → Buy $12
2026-02-10 init B. Riley Securities — → Buy $5
2025-12-03 init Roth Capital — → Buy $6
2025-11-28 reit HC Wainwright & Co. Buy → Buy $12
2025-10-15 reit HC Wainwright & Co. Buy → Buy $12
2025-09-11 main HC Wainwright & Co. Buy → Buy $12
2025-04-10 reit HC Wainwright & Co. Buy → Buy $9
2025-01-24 main HC Wainwright & Co. Buy → Buy $9
2024-06-03 reit HC Wainwright & Co. Buy → Buy $7
2024-04-16 main HC Wainwright & Co. Buy → Buy $7
2023-10-18 reit HC Wainwright & Co. Buy → Buy $8
2023-06-26 reit HC Wainwright & Co. Buy → Buy $8
2023-06-06 reit HC Wainwright & Co. — → Buy $8
2023-05-09 main HC Wainwright & Co. — → Buy $8
2020-08-18 main HC Wainwright & Co. — → Buy $20
2020-01-13 reit HC Wainwright & Co. — → Buy $26
2019-12-24 reit HC Wainwright & Co. — → Buy $12
2019-07-22 init HC Wainwright & Co. — → Buy $10
2018-11-19 down Ladenburg Thalmann Buy → Neutral —
2018-01-31 init Ladenburg Thalmann — → Buy $2
News
RSS: Latest MBOT news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
14.74
+26.82%
11.62
+14.69%
10.14
-24.57%
13.44
Research And Development
6.28
-5.23%
6.63
+15.83%
5.72
-26.01%
7.74
Selling General And Administration
8.25
+67.59%
4.92
+13.99%
4.32
-22.65%
5.58
General And Administrative Expense
8.25
+67.59%
4.92
+13.99%
4.32
-22.65%
5.58
Salaries And Wages
4.57
+49.92%
3.05
+37.99%
2.21
-30.43%
3.18
Other Gand A
3.28
+129.69%
1.43
-14.18%
1.66
-0.36%
1.67
Other Operating Expenses
0.21
+187.84%
0.07
-22.11%
0.10
-20.83%
0.12
Total Expenses
14.74
+26.82%
11.62
+14.69%
10.14
-24.57%
13.44
Operating Income
-14.74
-26.82%
-11.62
-14.69%
-10.14
+24.57%
-13.44
Total Operating Income As Reported
-14.74
-26.82%
-11.62
-17.96%
-9.86
+25.80%
-13.28
EBITDA
-14.70
-27.41%
-11.53
-15.00%
-10.03
+24.78%
-13.34
Normalized EBITDA
-14.70
-27.41%
-11.53
-25.40%
-9.20
+32.12%
-13.55
Reconciled Depreciation
0.05
-48.35%
0.09
-14.15%
0.11
+3.92%
0.10
EBIT
-14.74
-26.82%
-11.62
-14.69%
-10.14
+24.57%
-13.44
Total Unusual Items
—
0.00
+100.00%
-0.83
-486.98%
0.21
Total Unusual Items Excluding Goodwill
—
0.00
+100.00%
-0.83
-486.98%
0.21
Special Income Charges
—
0.00
+100.00%
-0.83
-650.99%
0.15
Other Special Charges
—
—
0.83
+632.05%
-0.16
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Pretax Income
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Net Non Operating Interest Income Expense
1.28
+606.04%
0.18
-20.18%
0.23
+322.22%
0.05
Net Interest Income
1.28
+606.04%
0.18
-20.18%
0.23
+322.22%
0.05
Interest Income Non Operating
—
—
0.28
+424.07%
0.05
Interest Income
—
—
0.28
+424.07%
0.05
Other Income Expense
0.32
—
-0.83
-486.98%
0.21
Other Non Operating Income Expenses
0.32
—
—
—
Gain On Sale Of Security
—
—
-0.06
-185.94%
0.06
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Net Income From Continuing Operation Net Minority Interest
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Net Income From Continuing And Discontinued Operation
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Net Income Continuous Operations
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Normalized Income
-13.14
-14.85%
-11.44
-15.49%
-9.91
+25.97%
-13.38
Net Income Common Stockholders
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Diluted EPS
-0.29
+60.27%
-0.73
+30.48%
-1.05
+41.99%
-1.81
Basic EPS
-0.29
+60.27%
-0.73
+30.48%
-1.05
+41.99%
-1.81
Basic Average Shares
45.79
+192.69%
15.64
+53.38%
10.20
+40.49%
7.26
Diluted Average Shares
45.79
+192.69%
15.64
+53.38%
10.20
+40.49%
7.26
Diluted NI Availto Com Stockholders
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Depreciation Amortization Depletion Income Statement
—
—
—
—
Depreciation And Amortization In Income Statement
—
—
—
—
Depreciation Income Statement
—
—
—
—
Gain On Sale Of PPE
—
0.00
+100.00%
-0.00
+60.00%
-0.01
Insurance And Claims
0.39
-11.09%
0.44
+0.00%
0.44
-39.70%
0.73
Total Other Finance Cost
-1.28
-606.04%
-0.18
+20.18%
-0.23
—
Line Item Trend 2023-12-31
Total Assets
8.33
Current Assets
7.92
Cash Cash Equivalents And Short Term Investments
6.38
Cash And Cash Equivalents
2.47
Cash Equivalents
0.00
Cash Financial
2.47
Other Short Term Investments
3.92
Receivables
1.49
Other Receivables
1.49
Loans Receivable
—
Inventory
—
Raw Materials
—
Work In Process
—
Prepaid Assets
—
Restricted Cash
0.05
Total Non Current Assets
0.41
Net PPE
0.41
Gross PPE
0.90
Accumulated Depreciation
-0.49
Properties
0.00
Buildings And Improvements
0.26
Machinery Furniture Equipment
0.41
Other Properties
—
Leases
0.23
Non Current Prepaid Assets
—
Other Non Current Assets
—
Total Liabilities Net Minority Interest
3.83
Current Liabilities
3.79
Payables And Accrued Expenses
2.79
Payables
0.36
Accounts Payable
0.36
Current Accrued Expenses
2.43
Pensionand Other Post Retirement Benefit Plans Current
0.72
Current Debt And Capital Lease Obligation
0.19
Current Capital Lease Obligation
0.19
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
0.08
Total Non Current Liabilities Net Minority Interest
0.04
Long Term Debt And Capital Lease Obligation
0.04
Long Term Capital Lease Obligation
0.04
Stockholders Equity
4.50
Common Stock Equity
4.50
Capital Stock
0.12
Common Stock
0.12
Share Issued
11.71
Ordinary Shares Number
11.71
Treasury Shares Number
0.00
Additional Paid In Capital
83.88
Retained Earnings
-79.50
Total Equity Gross Minority Interest
4.50
Total Capitalization
4.50
Working Capital
4.13
Invested Capital
4.50
Total Debt
0.23
Capital Lease Obligations
0.23
Net Tangible Assets
4.50
Tangible Book Value
4.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.05
-47.80%
-8.83
-3.45%
-8.53
+26.11%
-11.55
Cash Flow From Continuing Operating Activities
-13.05
-47.80%
-8.83
-3.45%
-8.53
+26.11%
-11.55
Net Income From Continuing Operations
-13.14
-14.85%
-11.44
-6.55%
-10.74
+18.44%
-13.17
Depreciation Amortization Depletion
0.05
-48.35%
0.09
-14.15%
0.11
+3.92%
0.10
Depreciation
0.05
-48.35%
0.09
-14.15%
0.11
+3.92%
0.10
Depreciation And Amortization
0.05
-48.35%
0.09
-14.15%
0.11
+3.92%
0.10
Other Non Cash Items
—
0.23
-67.32%
0.72
+6066.67%
-0.01
Stock Based Compensation
1.06
-21.65%
1.35
-3.23%
1.39
-20.43%
1.75
Operating Gains Losses
—
—
0.00
-60.00%
0.01
Unrealized Gain Loss On Investment Securities
—
—
—
-0.01
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.00
-60.00%
0.01
Change In Working Capital
-1.01
-207.01%
0.94
+8663.64%
-0.01
+95.18%
-0.23
Change In Inventory
-0.58
0.00
—
—
Change In Prepaid Assets
-0.92
-1431.88%
0.07
-89.73%
0.67
+5069.23%
0.01
Change In Payables And Accrued Expense
0.49
-43.30%
0.87
+227.82%
-0.68
-183.40%
-0.24
Investing Cash Flow
-72.38
-4809.43%
1.54
-22.10%
1.97
+151.43%
-3.84
Cash Flow From Continuing Investing Activities
-72.38
-4809.43%
1.54
-22.10%
1.97
+151.43%
-3.84
Net PPE Purchase And Sale
-0.06
-140.00%
-0.03
+24.24%
-0.03
+60.71%
-0.08
Purchase Of PPE
-0.06
-140.00%
-0.03
+24.24%
-0.03
+60.71%
-0.08
Capital Expenditure
-0.06
-140.00%
-0.03
+24.24%
-0.03
+60.71%
-0.08
Net Investment Purchase And Sale
-72.32
-4730.22%
1.56
-22.13%
2.01
+153.46%
-3.75
Purchase Of Investment
-82.93
-1519.65%
-5.12
+49.11%
-10.06
-168.12%
-3.75
Sale Of Investment
10.60
+58.67%
6.68
-44.62%
12.07
0.00
Financing Cash Flow
86.24
+986.69%
7.94
+21.01%
6.56
+51.67%
4.32
Cash Flow From Continuing Financing Activities
86.24
+986.69%
7.94
+21.01%
6.56
+51.67%
4.32
Net Common Stock Issuance
86.24
+986.68%
7.94
+21.01%
6.56
+51.67%
4.32
Proceeds From Stock Option Exercised
0.00
0.00
—
—
Changes In Cash
0.81
+25.39%
0.65
+32400.00%
-0.00
+99.98%
-11.06
Beginning Cash Position
3.16
+25.67%
2.52
-0.08%
2.52
-81.45%
13.58
End Cash Position
3.97
+25.61%
3.16
+25.67%
2.52
-0.08%
2.52
Free Cash Flow
-13.11
-48.06%
-8.85
-3.34%
-8.57
+26.36%
-11.63
Interest Paid Supplemental Data
—
—
—
—
Common Stock Issuance
86.24
+986.68%
7.94
+21.01%
6.56
+51.67%
4.32
Issuance Of Capital Stock
86.24
+986.68%
7.94
+21.01%
6.56
+51.67%
4.32
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category